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ABSTRACT
Objective: Stroke-risk in atrial fibrillation (AF) can be
significantly reduced by appropriate thromboembolic
prophylaxis. However, National Institute for Health and
Care Excellence estimates suggest that up to half of
eligible patients with AF are not anticoagulated, with
severe consequences for stroke prevention. We aimed
to determine the outcome of an innovative Primary
Care AF (PCAF) service on anticoagulation uptake in a
cohort of high-risk patients with AF in the UK.
Methods: The PCAF service is a novel cooperative
pathway providing specialist resources within general
practitioner (GP) practices. It utilises a four-phase
protocol to identify high-risk patients with AF
(CHA2DS2-VASc ≥1) who are suboptimally
anticoagulated, and delivers Consultant-led
anticoagulation assessment within the local GP
practice. We assessed rates of anticoagulation in high-
risk patients before and after PCAF service intervention,
and determined compliance with newly-initiated
anticoagulation at follow-up.
Results: The PCAF service was delivered in 56 GP
practices (population 386 624; AF prevalence 2.1%)
between June 2012 and June 2014. 1579 high-risk
patients with AF with suboptimal anticoagulation (either
not taking any anticoagulation or taking warfarin but with
a low time-in-therapeutic-range) were invited for review,
with 86% attending. Of 1063 eligible patients on no
anticoagulation, 1020 (96%) agreed to start warfarin
(459 (43%)) or a non-vitamin K antagonist oral
anticoagulant (NOAC, 561 (53%)). The overall proportion
of eligible patients receiving anticoagulation improved
from 77% to 95% (p<0.0001). Additionally, 111/121
(92%) patients suboptimally treated with warfarin agreed
to switch to a NOAC. Audit of eight practices after 195
(185–606) days showed that 90% of patients started on
a new anticoagulant therapy had continued treatment.
Based on data extrapolated from previous studies,
around 30–35 strokes per year may have been prevented
in these previously under-treated high-risk patients.
Conclusions: Systematic identification of patients with
AF with high stroke-risk and consultation in PCAF
consultant-led clinics effectively delivers oral
anticoagulation to high-risk patients with AF in the
community.
INTRODUCTION
Atrial ﬁbrillation (AF) is the cause of one in
four strokes,1–4 and approximately 5% of
unselected patients admitted for acute stroke
have previously undiagnosed AF.5 Optimal
prevention of AF-related strokes is of obvious
interest to patients with AF, as well as avoid-
ing the cost of stroke management to health-
care systems.6 Oral anticoagulation (OAC)
using vitamin K antagonists (most commonly
warfarin) or non-vitamin K antagonist oral
anticoagulant (NOAC) drugs can prevent
approximately two-thirds of AF-related
strokes.7 8 NOAC therapy can be delivered
with a simpler infrastructure in a cost-
effective way,9–11 and with a lower risk for
bleeding, especially for intracranial haemor-
rhage.8 12 Despite the clear beneﬁts in high-
risk patients with AF, OAC is underused in
patients with AF: the National Institute for
Health and Clinical Excellence (NICE) esti-
mates that 42% of patients that should be
anticoagulated are not,13 and similar observa-
tions have been made in other countries.14 15
The reasons for this are likely to be multifac-
torial, including concerns from general prac-
titioners (GPs) and patients regarding
Strengths and limitations of this study
▪ This study directly assessed the outcome of a
novel approach of delivering consultant-led antic-
oagulation assessment clinics in general practi-
tioner practices.
▪ The study was not performed as a controlled
trial.
▪ Only a random sample of the patients was
assessed to ascertain adherence to anticoagula-
tion therapy.
▪ Our estimates on stroke prevention through the
intervention are based on estimates of the effect
of anticoagulation derived from other studies.
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bleeding risk, the need for regular International
Normalised Ratio (INR) monitoring on vitamin K
antagonists, unsystematic identiﬁcation and manage-
ment of patients with AF in need of OAC and lack of
awareness of this need.
There are some data that hospital clinicians with spe-
cialist training in the management of AF will achieve
higher anticoagulation rates in patients with AF than
GPs or internists.16 However, most patients with AF are
not under specialist care in the National Health Service
(NHS). The recently-released AF management guideline
from NICE focuses on the need for improved rates of
anticoagulation in patients with AF at elevated risk of
stroke,17 and a related NICE document ‘How to Change
Practice’ promotes the concept of better integration
between primary and secondary care.18
Foreseeing this healthcare priority, we instituted an
innovative Primary Care Atrial Fibrillation (PCAF)
Service in GP practices in Merseyside in the UK in June
2012. The PCAF service provides a hospital
consultant-led service offering specialist expertise in the
management of patients with AF at high stroke-risk
within GP practices, and has now expanded to involve
GP practices across England and Wales. We aimed to
determine the outcomes of this service over the 2 years
since its inception.
METHODS
The PCAF service
PCAF service staff
The PCAF service involved three groups of staff:
1. Trained healthcare professionals with a nursing or
allied health professional background (termed ‘PCAF
professionals’)
2. Consultant Cardiologists or Consultant Stroke
Physicians from local hospitals
3. Ofﬁce administrative staff.
Practice enrolment
GP practices were informed of the availability of the
service through direct systematic marketing or by
approaching CCG Commissioning Managers and/or
Medicines Management teams. As the service expanded,
interest was expressed from GP practices based on
recommendations from previously-enrolled practices.
Pathway
In each enrolled GP practice, the PCAF service was deliv-
ered via four phases, with an additional practice educa-
tion programme (ﬁgure 1).
Phase 1
The PRIMIS+ AF Query Case Finder Set is an automated
electronic tool used widely in primary care in the UK. It
is used to search electronic patient records to identify
entries in the medical history that may potentially indi-
cate a diagnosis of AF (eg, ‘irregular pulse’ or ‘digoxin
therapy’). In phase 1 of the PCAF service, this tool was
used to search the records of all patients not currently
listed on the practice’s AF register in order to identify
any further patients with a possible or probable diagno-
sis of AF. This was to ensure that no high-risk patients
were missed by virtue of not currently being listed on
the AF register. A PCAF professional then performed a
comprehensive case note review of all identiﬁed
patients, with the outcome being one of:
▸ AF conﬁrmed;
▸ Patient does not have AF;
▸ Patient referred for further investigation to ascertain
a diagnosis of AF.
If required, specialist support was provided by a PCAF
Consultant Physician.
Phase 2
The GRASP-AF tool was then applied. This is an audit
tool created in partnership with NHS Improving Quality
that is used to risk-stratify patients and determine their
current anticoagulation therapy.19 This tool was used to
audit all patients on the AF register, including those
added following phase 1, to identify those at high-risk of
stroke in whom anticoagulation is recommended or
should be considered (CHA2DS2-VASc score ≥1, exclud-
ing females with no additional risk factors) but who
were not currently receiving anticoagulation therapy.20
The PCAF professional performed a comprehensive case
note review of all identiﬁed patients, with the outcome
being one of:
▸ AF conﬁrmed and patient eligible for a PCAF
face-to-face review;
▸ AF conﬁrmed but only eligible for a ‘virtual notes
review’ (applicable to patients who were either house-
bound or were resident in a nursing home and were
unable to attend the clinic);
▸ Patient not eligible to be invited for review in a PCAF
clinic as anticoagulation therapy would not be indi-
cated. This was applicable to the following groups of
patients:
1. Patients who had previously suffered an episode of
AF but this had subsequently resolved (eg, a single
episode of AF following a surgical procedure or AF
related to thyrotoxicosis which had since been suc-
cessfully treated);
2. Patients with a current contraindication to anticoagu-
lation (deﬁned as on-going or recent untreated
major bleeding, previous intracranial bleeding or a
severe risk of bleeding);
3. Patients in whom, after a thorough review of their
clinical records, it was found that there was no evi-
dence that they had ever had AF.
In addition, all patients who were currently receiving
warfarin had their time-in-therapeutic-range (TTR) over
the prior 6-month period calculated using an electronic
TTR calculator; those who had a suboptimal TTR
(deﬁned as <65%) were also deemed to be at high risk
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and therefore eligible for review to assess the optimal
anticoagulation strategy.17
Phase 3
Two weeks before the scheduled PCAF clinic, an ofﬁce
administrator sent a letter to patients eligible for clinic
review inviting them to attend a PCAF appointment.
Literature detailing the reason for the clinic review and
the risks and beneﬁts of anticoagulation was also
included with the invitation letter. Patients were then
contacted by telephone 1 week prior to their appoint-
ment to explain the service and answer any queries, and
again 1 day prior in order to minimise non-attendance
(‘call and recall’ approach).
Phase 4
A consultant cardiologist or consultant stroke physician
delivered PCAF anticoagulation assessment clinics within
the patient’s GP practice. The patient’s current treat-
ment was reviewed and, where appropriate, anticoagula-
tion was prescribed in accordance with NICE guidelines
and/or the local medicines management formulary.
Other aspects of medical treatment for AF, such a rate
or rhythm control therapies, were also reviewed where
appropriate.
Education
GPs, nurse clinicians, practice nurses and practice phar-
macists were invited to take part in the consultant-led
PCAF anticoagulation clinics, allowing opportunities for
shared learning and discussion of individual cases.
Additionally, staff members from enrolled practices had
access to a consultant-led education programme.
Practice staff attending this programme could count this
towards their Continuing Professional Development/
Continuing Medical Education targets for their annual
appraisal but no other incentives for attendance were
offered.
Assessment of outcomes
The eventual outcome for each identiﬁed high-risk
patients with AF in the PCAF pathway was recorded in
the individual practices’ network drive as well as on a
central database. We assessed the uptake of anticoagula-
tion in appropriate patients after intervention of the
PCAF service compared to before. To assess on-going
compliance with the prescribed treatment, case notes
for patients who were prescribed a new or alternative
anticoagulant agent were reviewed in a subset of GP
practices in which the PCAF pathway had been com-
pleted at least 6 months prior. As per the deﬁnitions
listed by the NHS Health Research Authority, this study
was classiﬁed as a service evaluation rather than research
and therefore did not require ethical review by a
Research Ethics Committee.
Statistical analysis
Continuous variables that are normally distributed are
expressed as mean±SD, and variables that are not nor-
mally distributed are expressed as a median (IQR).
Proportions were compared using the χ2 test. All tests
Figure 1 Graphic showing the four phases of the Primary Care Atrial Fibrillation service pathway.
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were two-sided and p<0.05 was considered statistically
signiﬁcant.
RESULTS
To date, the PCAF pathway has been implemented in 56
GP practices serving a population of 386 624 registered
patients. For an average practice of 6000–7000 patients,
it took approximately 12 h for a PCAF professional to
utilise the search tools and perform a review of patient
case notes, around 3 h for administrative staff to send
invitation letters and contact patients by phone, and
approximately 4 h for a physician (supported by a PCAF
professional) to deliver the anticoagulation assessment
clinic.
Outcomes from the four phases of the PCAF pathway
are detailed below.
Patients not on anticoagulation
Phase 1
For the 56 practices, clariﬁcation of the AF register
resulted in a total population with AF of 7945 patients
(prevalence 2.1%) (ﬁgure 2).
Phase 2
A total of 7487 (94%) of these patients had a
CHA2DS2-VASc score of ≥1, of whom 4178 (56%; per-
practice range 29%–78%) were already on anticoagula-
tion. Case notes were then reviewed for 2914 patients
not on anticoagulation, with 1335 (46%) patients
judged not to be eligible for anticoagulation. This was
due to either: anticoagulation not indicated (female
gender the only risk factor), a contraindication to antic-
oagulation, an incorrect Read code for AF (commonly
due to the application of an AF Read code at the time
of investigation but not removed when AF not found) or
resolution of AF. This left 1579 patients who were eli-
gible for, but not on, anticoagulation.
Phase 3
These 1579 patients were invited to PCAF anticoagula-
tion clinics using the ‘call and recall’ approach, of
whom 1358 (86%) attended for review within 2 weeks of
invitation. Only 221 (14%) patients did not attend for
review, with 13 (1%) declining the invitation and 208
(13%) failing to attend.
Phase 4
Following review in clinic of the 1358 patients who
attended, 1063 (78%) were conﬁrmed to be eligible for
anticoagulation. Of these patients, 84% had a
CHA2DS2-VASc score of 2 or more, with the remaining
16% patients having a score of 1. Eighty-ﬁve per cent of
these patients were also eligible using the criterion of a
CHADS2 score ≥1, with 52% having a CHADS2 score
≥2. Antiplatelet therapy was being taken by 71% of
patients at the time of review. Eleven per cent (n=117)
of the 1063 patients not on anticoagulation had
previously suffered a stroke or transient ischaemic attack
(TIA).
Following the consultation, 1020 (96%) patients
agreed to start anticoagulation (warfarin in 43% and a
NOAC in 53%). With regard to the 561 patients started
on a NOAC, 12% of patients had previously tried but
not tolerated warfarin, 21% had previously declined war-
farin and 67% preferred a NOAC over warfarin. NOAC
prescription was distributed among the three agents as
follows: apixaban—17%, dabigatran—49% and rivaroxa-
ban—34%.
Of the 43 (4%) patients that did not agree to start
anticoagulation therapy at the time of their consultation,
only 16 patients declined treatment, with the remaining
27 preferring to defer their decision pending further
discussion with their GP.
Overall, taking into account all exclusions (patients
deemed not to have AF and those ineligible for anticoa-
gulation), the total number of patients eligible for antic-
oagulation registered to these 56 GP practices was 5471.
With the intervention of the PCAF service, the propor-
tion receiving anticoagulation improved from 77%
(4187/5471) to 95% (5207/5471) (p<0.0001).
Patients with a suboptimal TTR
A total of 4178 patients in the 56 GP practices were
already anticoagulated with warfarin (ﬁgure 3). Case
notes and INR records were reviewed for 3295 of these
patients. A total of 387 (12%) patients with a suboptimal
TTR (<65%) were identiﬁed and invited for review, of
whom 83% attended. After clinical review, the majority
of patients (62%) were advised to continue on warfarin.
Reasons for this decision included: an improved TTR
over recent readings, a clear reason for previous INR
variability (such as previous courses of antibiotics), sig-
niﬁcant renal dysfunction contraindicating use of a
NOAC, compliance issues that could be addressed at the
Figure 2 CONSORT flow chart showing outcomes for
patients not on anticoagulation identified through the PCAF
service. AF, atrial fibrillation, OAC, oral anticoagulation; PCAF,
Primary Care Atrial Fibrillation.
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clinic visit or concerns over non-compliance, in which
case warfarin was felt more appropriate to a NOAC as
compliance could continue to be assessed through INR
monitoring. One hundred and twenty-one (38%)
patients were offered a NOAC, with 111 (92%) agreeing
to change therapy.
Follow-up data
Eight random GP practices that had hosted the PCAF
service at least 6 months previously were audited. A total
of 87 patients initiated on a new anticoagulant agent
were identiﬁed (median follow-up 195 (IQR 185–606)
days). The characteristics of these patients (age 75
±9 years, 60% male, median CHADS2 score 2 (1–3),
median CHA2DS2-VASc score 3 (2–4)) were similar to
those of the 1063 patients invited to PCAF clinics (age
74±10 years, 53% male, CHADS2 score 2 (1–3),
CHA2DS2-VASc score 4 (2–6)). Twenty-ﬁve patients had
been started on warfarin, 51 patients had been initiated
on a NOAC as a ﬁrst-line agent, and 11 patients had
been switched from warfarin to a NOAC.
Of the 25 patients started on warfarin, 19 (76%)
remained on this treatment at the time of the audit.
One further patient had suffered recurrent deep vein
thromboses on warfarin and had been switched by a
consultant haematologist to a low-molecular-weight
heparin, and therefore remained anticoagulated. Two
patients had died during the follow-up period. In both
cases, warfarin had been continued at the time of death
and the deaths were unrelated to bleeding or stroke.
Only 3 of the 25 patients requested to stop warfarin,
resulting in an overall compliance rate of 88%.
For the 62 patients initiated on a NOAC, 50 (81%)
remained on a NOAC. Three patients (all of whom had
previously not been on any anticoagulation) had
requested to switch to warfarin and remained anticoagu-
lated. Three patients had died during follow-up; they had
each remained on NOAC therapy up to the time of death
and neither bleeding nor stroke were related to the cause
of death. In one case, a new diagnosis of signiﬁcant renal
dysfunction was made (estimated glomerular ﬁltration
rate 35 mL/min) and NOAC therapy was stopped by the
patient’s GP. Five patients requested to stop anticoagula-
tion, with three of these switching to an antiplatelet
agent. Overall, the compliance rate with NOAC treatment
was 85% (53/62), and with any anticoagulation therapy
was 90% (56/62).
Taking both the warfarin and NOAC groups into
account, 78 of 87 (90%) patients had continued anticoa-
gulation following PCAF intervention, either the initial
agent or an alternative.
DISCUSSION
During the implementation of PCAF, we made several
observations that can inform the future management of
patients with AF: (1) there is a signiﬁcant proportion of
patients with AF at high risk of stroke in primary care
that are not treated with OAC (23%), with a further
group of patients inadequately anticoagulated with war-
farin, and (2) a consultant-led anticoagulation service in
the community will get the majority of these patients
anticoagulated, including the facility for individual,
patient-oriented anticoagulation decisions. Importantly,
the PCAF intervention led to high compliance with
newly-initiated anticoagulation. Taken together, PCAF
has the potential to improve the utilisation of OAC, and
to prevent strokes in high-risk patients with AF.
Evidence generated in the past decade underpins the
use of OAC in the vast majority of patients with AF, that is,
those with stroke risk factors (at least one, and certainly
two of the CHA2DS2-VASc risk factors).
21 22 This was
reﬂected in previous NICE guidance on AF, published in
June 2006, that listed all but female gender of the
CHA2DS2-VASc risk factors for use in stroke-risk stratiﬁca-
tion.23 Hence, guidance applicable in the Merseyside
region has effectively advocated anticoagulation use since
2006 in most patients who would now accrue a score of 1
or more under the CHA2DS2-VASc scoring system,
though this has been substantially clariﬁed in the latest
guidance.17 Despite this guidance, the PCAF programme
identiﬁed 1063 high-risk patients without OAC, of whom
892 (84%) had a CHA2DS2-VASc score ≥2 and 171 (16%)
had a CHA2DS2-VASc score of 1.
21 22
Clinician-initiated health improvement reviews in
primary care are known to commonly suffer from low
attendance rates. However, the PCAF service was able to
achieve an overall attendance rate of 85%. This is likely
to be in part due to the ‘call and recall’ approach
employed, with a letter invitation followed by phone call
reminders 1 week and again 1 day prior to the appoint-
ment. Hence, this study corroborates prior studies
showing that that attendance rates can be improved with
telephone reminders.24 25 In addition, it is possible that
improved attendance may also have been related to the
Figure 3 CONSORT flow chart showing outcomes for
patients on warfarin with a suboptimal TTR identified through
the PCAF service. INR, International Normalised Ratio; PCAF,
Primary Care Atrial Fibrillation; TTR, time-in-therapeutic
range; NOAC, non-vitamin K antagonist oral anticoagulant.
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opportunity to see a specialist in the setting of their GP
surgery.
Finally, the PCAF service has demonstrated a marked
increase in the uptake of anticoagulation in high-risk
patients with AF, including those who had previously
been offered but refused anticoagulation. In some cases,
the option of NOAC agents that do not require monitor-
ing will have facilitated this decision, but past research
has also shown that rates of uptake are dependent on
patient perceptions of the value of anticoagulation.26 We
believe that the increased experience with managing
anticoagulation in patients with AF, particularly with
regard to NOACs, possessed by secondary care physi-
cians in the ﬁelds of cardiology and stroke medicine
helps to alter patients’ perceptions in many cases
towards acceptance and continuation of anticoagulation.
Prevention of strokes by the PCAF service
The PCAF service predominantly identiﬁes the at-risk
primary prevention population, though a small propor-
tion (11%) had suffered a previous stroke or TIA. In
primary prevention patients, approximately 35 patients
need to be treated with warfarin for a year to prevent
one stroke, whereas, in patients with a prior stroke, the
number needed to treat (NNT) is around 12.7 27
Equivalent data are not available for the three available
NOACs, but all have shown equivalent or superior efﬁ-
cacy compared to warfarin,28–30 and modelling data
have suggested a lower NNT compared to warfarin for
each agent.31 In this study, 1020 patients were newly
anticoagulated due to the PCAF intervention, of whom
111 were secondary prevention patients. Compliance
with therapy at follow-up was 90%, or approximately 918
patients. Furthermore, there were 111 patients who were
previously on warfarin with a suboptimal TTR who have
now started a NOAC. Based on the estimated efﬁcacy,
the intervention of the PCAF service may have pre-
vented around 30–35 strokes per year in these 56 GP
practices.
The PCAF service as a model of care
In the traditional model of care, only a small proportion
of patients typically gain access to specialist hospital-
based resources. Within the ﬁeld of AF, these are usually
patients requiring input regarding rhythm management.
At the same time, however, it is extremely difﬁcult for
primary care clinicians to not only be aware of develop-
ments in all areas of medicine, but also to have the
knowledge and conﬁdence to implement them. With
speciﬁc regard to anticoagulation in patients with AF in
primary care, familiarity with the CHA2DS2-VASc scoring
system may not be universal, particularly as the CHADS2
score is still utilised for the Quality and Outcomes
Framework (QOF). Additionally, primary care clinicians
may have little or no experience with the NOAC agents,
in part due to their relatively recent release and
approval, and in part due to the limited number of con-
ditions for which they are indicated.
The PCAF service took an innovative approach by
bridging this boundary between primary and secondary
care, providing specialist resources within the primary
care setting. This strategy has two distinct advantages.
First, patients currently managed solely within primary
care are reviewed and, where appropriate, their anticoa-
gulation treatment is optimised. Second, the educational
legacy left within the GP practice following completion
of the PCAF pathway enables such optimal treatment to
be carried forward for future patients.
Limitations
The PCAF intervention was not performed as a con-
trolled trial, and our estimates on stroke prevention
through the intervention are based on estimates of the
effect of OAC derived from other studies. Furthermore,
we only had resources to audit a random sample of the
patients (8 GP practices) to ascertain adherence to
anticoagulation therapy, and did not directly assess antic-
oagulation in all patients entered into PCAF.
CONCLUSIONS
The PCAF service is an innovative care pathway bridging
the boundary between primary and secondary care.
Systematic identiﬁcation of patients with AF with high
stroke-risk and consultation in Consultant-led clinics
through this service effectively delivers OAC to high-risk
patients with AF in the community, with evidence of
excellent continued compliance with treatment.
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